The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer.
Eric Jeffrey Sherman
Research Funding - Novartis
Alan Loh Ho
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Matthew G. Fury
Research Funding - Novartis
Shrujal S. Baxi
No relevant relationships to disclose
Sofia Haque
No relevant relationships to disclose
Brynna Lane Lipson
No relevant relationships to disclose
Sarah Kurz
No relevant relationships to disclose
James A. Fagin
No relevant relationships to disclose
David G. Pfister
No relevant relationships to disclose